MCID: SYS047
MIFTS: 17

Systemic Lupus Erythematosus 7

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 7

MalaCards integrated aliases for Systemic Lupus Erythematosus 7:

Name: Systemic Lupus Erythematosus 7 54
Systemic Lupus Erythematosus, Susceptibility to, 7 13

Classifications:



External Ids:

OMIM 54 610065

Summaries for Systemic Lupus Erythematosus 7

MalaCards based summary : Systemic Lupus Erythematosus 7, is also known as systemic lupus erythematosus, susceptibility to, 7. An important gene associated with Systemic Lupus Erythematosus 7 is SLEB7 (Systemic Lupus Erythematosus, Susceptibility To, 7). The drugs Cyclophosphamide and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include t cells, liver and skin.

Description from OMIM: 610065

Symptoms & Phenotypes for Systemic Lupus Erythematosus 7

Clinical features from OMIM:

610065

Drugs & Therapeutics for Systemic Lupus Erythematosus 7

Drugs for Systemic Lupus Erythematosus 7 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2 Vaccines Phase 4,Phase 2,Phase 3
3 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
4 Alkylating Agents Phase 4,Phase 2,Phase 1
5 Antirheumatic Agents Phase 4,Phase 2,Phase 1
6
belimumab Approved Phase 3,Phase 2,Phase 1 356547-88-1 5957 10451420
7 Antibodies Phase 3,Phase 1,Phase 2
8 Immunoglobulins Phase 3,Phase 1,Phase 2
9 Heptavalent Pneumococcal Conjugate Vaccine Phase 2, Phase 3
10 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
11 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 1
12 Antimalarials Phase 3
13 Pharmaceutical Solutions Phase 3,Phase 1
14
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
15
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
16
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774
17
Lenograstim Approved Phase 2 135968-09-1
18
Mesna Approved Phase 2 3375-50-6 598
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
20
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
21
Promethazine Approved Phase 2 60-87-7 4927
22
rituximab Approved Phase 2 174722-31-7 10201696
23
Vidarabine Approved Phase 2 24356-66-9 32326 21704
24
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
25
Dehydroepiandrosterone Approved, Nutraceutical Phase 2 53-43-0 9860744
26 Adjuvants, Immunologic Phase 2
27 Hemagglutinins Phase 2
28 MF59 oil emulsion Phase 2
29 Liver Extracts Phase 1, Phase 2
30 Androgens Phase 2
31 Anesthetics Phase 2
32 Anesthetics, Local Phase 2
33 Anti-Allergic Agents Phase 2
34 Antiemetics Phase 2
35 Anti-Infective Agents Phase 2
36 Antimetabolites Phase 2,Phase 1
37 Antimetabolites, Antineoplastic Phase 2
38 Antineoplastic Agents, Hormonal Phase 2
39 Antipruritics Phase 2
40 Antiviral Agents Phase 2
41 Autonomic Agents Phase 2
42 Central Nervous System Depressants Phase 2
43 Dermatologic Agents Phase 2
44 Gastrointestinal Agents Phase 2
45 glucocorticoids Phase 2
46 Histamine Antagonists Phase 2
47 Histamine H1 Antagonists Phase 2
48
Histamine Phosphate Phase 2 51-74-1 65513
49 Hormone Antagonists Phase 2
50 Hormones Phase 2

Interventional clinical trials:

(show all 38)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children Recruiting NCT01861561 Phase 4 Low-dose intravenous cyclophosphamide;High-dose intravenous cyclophosphamide
3 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
4 A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01484496 Phase 3 Standard therapy
5 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
6 GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia Active, not recruiting NCT01345253 Phase 3 Belimumab;Placebo
7 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
8 Vaccination Against Influenza H1N1 in Rheumatic Diseases Unknown status NCT01006681 Phase 2
9 Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Unknown status NCT01661842 Phase 1, Phase 2
10 Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy. Unknown status NCT01687192 Phase 2
11 Auto-immunity in Lupus Patients After Influenza Vaccine Completed NCT01072734 Phase 2 Vaccine
12 A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector Completed NCT02124798 Phase 2
13 DHEA Treatment for Sjogren's Syndrome Completed NCT00001598 Phase 2 Dehydroepiandrosterone
14 PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus Completed NCT01162681 Phase 2 A-623;A-623;A-623
15 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed NCT00076752 Phase 2 fludarabine phosphate;cyclophosphamide;methylprednisolone;Diphenhydramine;Mesna
16 A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Completed NCT00657189 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;Placebo
17 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
18 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2
19 JBT-101 in Systemic Lupus Erythematosus (SLE) Not yet recruiting NCT03093402 Phase 2 JBT-101;Placebo
20 Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE) Terminated NCT00732940 Phase 2 Belimumab 100 mg SC;Belimumab 100 mg SC
21 A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus Completed NCT02391259 Phase 1 AMG 557;Placebo
22 A Study of AMG 557 in Adults With Systemic Lupus Erythematosus Completed NCT00774943 Phase 1 AMG 557
23 Skin Denervation in Systemic Lupus Erythematosus Completed NCT00155532 Phase 1
24 Aspirin Resistance in Systemic Lupus Erythematosus (SLE) Completed NCT00731302 Phase 1 aspirin and meloxicam
25 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01686555 Phase 1 ABT-199
26 A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184 Completed NCT01953835 Phase 1 GSK2586184 standard formulation;Simvastatin;Rosuvastatin;GSK2586184 new formulation
27 Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00657007 Phase 1
28 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Completed NCT02106897 Phase 1 BIIB059;Placebo
29 Premature Coronary Artery Disease (CAD) in Severe Psoriasis Completed NCT00893126 Phase 1
30 Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01093911 Phase 1
31 Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects Completed NCT02151409 Phase 1 NNC 0151-0000-0000;NNC 0151-0000-0000;placebo
32 Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus Recruiting NCT02535689 Phase 1 Tofacitinib;Placebo
33 A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) Recruiting NCT03030976 Phase 1 cyclophosphamide;anti-CD19-CAR-T cells
34 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
35 Catalytic Antibodies and Lupus in Martinique Completed NCT01157468
36 International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus Completed NCT01509989
37 Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness Completed NCT02453880
38 Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection Not yet recruiting NCT02872506 Anti TNF

Search NIH Clinical Center for Systemic Lupus Erythematosus 7

Genetic Tests for Systemic Lupus Erythematosus 7

Anatomical Context for Systemic Lupus Erythematosus 7

MalaCards organs/tissues related to Systemic Lupus Erythematosus 7:

39
T Cells, Liver, Skin

Publications for Systemic Lupus Erythematosus 7

Variations for Systemic Lupus Erythematosus 7

Expression for Systemic Lupus Erythematosus 7

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 7.

Pathways for Systemic Lupus Erythematosus 7

GO Terms for Systemic Lupus Erythematosus 7

Sources for Systemic Lupus Erythematosus 7

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....